Nurix Issuance Of Capital Stock from 2010 to 2025

NRIX Stock  USD 15.45  0.45  3.00%   
Nurix Therapeutics Issuance Of Capital Stock yearly trend continues to be fairly stable with very little volatility. Issuance Of Capital Stock is likely to outpace its year average in 2025. During the period from 2010 to 2025, Nurix Therapeutics Issuance Of Capital Stock regression line of annual values had r-squared of  0.01 and arithmetic mean of  322,294,623. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
550.3 M
Current Value
577.8 M
Quarterly Volatility
156.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 326 K, Net Interest Income of 23.8 M or Interest Income of 23.8 M, as well as many indicators such as Price To Sales Ratio of 24.85, Dividend Yield of 0.0 or PTB Ratio of 2.66. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Latest Nurix Therapeutics' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Nurix Therapeutics over the last few years. It is Nurix Therapeutics' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nurix Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Very volatile
   Issuance Of Capital Stock   
       Timeline  

Nurix Issuance Of Capital Stock Regression Statistics

Arithmetic Mean322,294,623
Geometric Mean0.00
Coefficient Of Variation48.69
Mean Deviation99,665,859
Median338,061,000
Standard Deviation156,924,882
Sample Variance24625.4T
Range577.8M
R-Value0.08
Mean Square Error26235T
R-Squared0.01
Significance0.78
Slope2,480,310
Total Sum of Squares369381.3T

Nurix Issuance Of Capital Stock History

2025577.8 M
2024550.3 M
2023478.5 M
2022null
202119.4 M
2020150.2 M

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' Issuance Of Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Issuance Of Capital Stock550.3 M577.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.